Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2015

View Archived Issues

Mitochondrial uncoupling has disease-modifying effects in mouse models of type 2 diabetes

Ultra-small nanoparticle probe for cancer diagnostics

Janssen Biotech forms license agreement with Vedanta Biosciences for VE-202

Moderna and Merck & Co. to develop mRNA-based antiviral treatments and vaccines

KalGene enters license agreement with NRC to develop Alzheimer's therapeutics

DSMB recommends continuation of phase III trial of masitinib for ALS

Catabasis patents novel fatty acid-drug conjugates for cancer

AstraZeneca's PEGASUS-TIMI 54 trial of Brilinta meets primary endpoint

Alnylam's RNAi therapy targeting antithrombin improves clotting in patients with hemophilia

Auris Medical updates on phase III trial of AM-101 in tinnitus

NantCell licenses anti-IGF-I receptor antibody ganitumab from Amgen

Companies investigate different approaches to tackling Ebola

Treeway and uniQure collaborate to develop gene therapy for ALS

FDA grants orphan drug status to OS-2966 and ulocuplumab for cancer

Intestinal FXR triggering mimics food intake and improves metabolic disease

Takeda divulges PK-R1 antagonists

Roche reports development of agents for psychiatric disorders

Orion prepares new androgen receptor and CYP17 inhibitors for prostate cancer

Cadila Pharmaceuticals presents novel MPGES-1 inhibitors

OncoMed enrolls first biomarker-selected patient in anti-Notch 1 expansion trial

Alexion describes pipeline outlook at JP Morgan Healthcare Conference

European Alzheimer's disease initiative EPAD is launched

Phase I results presented for AMG-377 treatment of gastrointestinal tumors

Neuropore and UCB collaborate in Parkinson's disease

AbbVie's Viekirax plus Exviera receives E.U. approval for chronic HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...